Latest News

Tuesday February 07, 2023

Congratulations to Kate Schroder,
2022 ASI AbbVie New Horizons Research Awardee


In 2022 we continued our partnership with AbbVie in bringing you the ASI AbbVie New Horizons Research Award.

We warmly congratulate
Kate Schroder
winner of the 2022 ASI AbbVie New Horizons Research Award.

We extend much gratitude to AbbVie, who have generously sponsored this prestigious award.



AbbVie is a global biopharmaceutical company committed to developing innovative therapies for some of the world’s most complex conditions. In Australia, we employ more than 450 people with our therapies currently benefiting more than 30,000 Australians across several therapeutic areas: Immunology, Oncology, Virology, Neuroscience, Eye Care and Aesthetics.

ASI AbbVie New Horizons Research Award


AbbVie is committed to moving science forward to further develop medicines that can change the lives of people living with immune-mediated conditions such as Autoimmunity and Inflammation. 

Within these therapeutic areas, AbbVie has identified gaps in immunology research, particularly in the areas of new biological pathways, druggable targets and biomarkers, leading to paucity of innovation in therapeutics and precision medicine.  

To encourage investment in emerging areas, AbbVie will sponsor a research award that recognises an exceptional Australian or New Zealand Researcher who is leading in future-focused research that has potential to advance scientific exploration in emerging areas. 


To support a mid career research Immunologist (10-20 years post-doctoral) with potential to advance research in emerging areas such as new biological pathways, druggable targets and biomarkers, within the fields of Autoimmunity, Inflammation, and other Immune-mediated Diseases (excluding Infectious Diseases).

The key objective of the ASI AbbVie New Horizons Research Award is to invigorate basic, translational or applied research in these areas of strategic importance. 


Learn more about the ASI AbbVie New Horizon Research Award

Back to All Blogs

© ASI 2021

ABN 76 330 189 856 | ARBN 084 971 559 | CAV A0016266B